Natera gets Japan PMDA authorization for Signatera in bladder cancer
Natera said Japan’s PMDA authorized its Signatera test as a companion diagnostic in muscle-invasive bladder cancer to guide adjuvant atezolizumab treatment.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.